We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
sarah
O'Brien
sarah.o’brien2@newcastle.ac.uk
Prof
sarah
O'Brien
sarah.o’brien2@newcastle.ac.uk
Intestinal infectious diseases
This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.
Infectious intestinal disease (IID), usually presenting as diarrhoea and vomiting (D&V), is frequently preventable. Though often mild and self-limiting, the fact that it is so common makes IID an important public health problem. In the mid 1990s around 1 in 5 people in England experienced IID in a year, costing around £0.75 billion. The economic impact comprised costs to the cases themselves, to the NHS and to employers in terms of time off work when sick, or time off work looking after someone who was sick. By the late 2000s IID across the UK had increased, affecting around 1 in 4 people. The estimated cost to the nation had also risen to approximately £9 billion. The IID1 Study (performed 1993-1996) and the IID2 Study (2008-2009) also helped us to understand the inaccuracies in national surveillance data. Now we want to measure IID burden again, to find out whether controls introduced by the Food Standards Agency have worked. We also want to re-calibrate national surveillance data. The Third Study of Infectious Intestinal Disease in the Community (IID3 Study), like its predecessors, comprises separate but related studies. We will estimate community IID rates in a prospective, all-age, population-based cohort study with weekly follow-up over a calendar year. We will also perform a prospective study of people presenting to their General Practice with IID symptoms. We will request faecal samples from all cases and test them for a very wide range of germs (pathogens), including markers of antimicrobial resistance, using modern molecular methods. We will also audit routine clinical and laboratory practice in primary care. We will calculate rates of IID overall, and pathogen-specific rates, in the community and presenting to Primary Care and compare the results with the previous studies. Finally, we will combine all our results to re-calibrate national surveillance data.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
People not registered with a GP will be excluded by our recruitment methods. In addition those living in prisons will not be included in the study. Finally, patients who lack capacity to give informed consent will be excluded from the study. If a patient should lose capacity during the course of the study, or decide to leave the study, we will include their data up to the point that they leave the study and we have made this clear in the participant information sheet. Exclusion criteria for Cohort 1: We will exclude households where a member of the household has inflammatory bowel disease (IBD). The reason for excluding people with IBD is that it difficult to define an onset date. Exclusion criteria for Cohorts 2 and 3: We will exclude people with IBD.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Newcastle Upon Tyne and funded by Food Standards Agency .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 53095
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
